<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> in the western world </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, which develop from <z:mpath ids='MPATH_270'>adenoma</z:mpath> precursor lesions, show gain of chromosome arm 20q, where BCL2L1 is located </plain></SENT>
<SENT sid="2" pm="."><plain>BCL2L1 is an important <z:mpath ids='MPATH_3'>apoptosis</z:mpath> regulating gene that codes for both an anti-apoptotic (Bcl-x(L)) and a pro-apoptotic (Bcl-x(S)) splice variant </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the present study was to investigate whether BCL2L1 contributes to 20q gain-driven colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath>-to-<z:mp ids='MP_0002038'>carcinoma</z:mp> progression </plain></SENT>
<SENT sid="4" pm="."><plain>To this end, the functional role of BCL2L1 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related processes was investigated, and differences in BCL2L1 DNA, <z:chebi fb="2" ids="33699">mRNA</z:chebi>, and protein levels were compared between colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, as well as between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with and without 20q gain </plain></SENT>
<SENT sid="5" pm="."><plain>Down-modulation of BCL2L1 inhibited cell viability and anchorage-independent growth of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, while invasion was not affected </plain></SENT>
<SENT sid="6" pm="."><plain>BCL2L1 DNA copy number and protein expression were increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> compared to <z:mpath ids='MPATH_270'>adenomas</z:mpath> (p = 0.00005 and p = 0.03, respectively), while <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was not </plain></SENT>
<SENT sid="7" pm="."><plain>Differences in BCL2L1 protein expression were even more pronounced between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with and without 20q gain (p = 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, BCL2L1 is functionally involved in several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related processes and its protein expression is associated with 20q gain </plain></SENT>
<SENT sid="9" pm="."><plain>This supports a role for 20q gain-dependent expression of BCL2L1 in colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath>-to-<z:mp ids='MP_0002038'>carcinoma</z:mp> progression </plain></SENT>
<SENT sid="10" pm="."><plain>However, the absence of a direct correlation between BCL2L1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression implies that BCL2L1 protein expression is regulated at the post-transcriptional level by a distinct factor on the 20q amplicon (eg ZNF217, AURKA or miRNAs) </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, even though BCL2L1 affects <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> biology in a 20q gain-dependent manner, it is not likely to be a driver of chromosome 20q gain associated <z:mpath ids='MPATH_270'>adenoma</z:mpath>-to-<z:mp ids='MP_0002038'>carcinoma</z:mp> progression </plain></SENT>
</text></document>